ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RCPT (MM)

231.96
0.00 (0.00%)
15 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:RCPT NASDAQ Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 231.96 0.00 01:00:00

Receptos to Hold Second Quarter 2013 Financial Results Conference Call and Webcast

01/08/2013 1:01pm

GlobeNewswire Inc.


RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more RECEPTOS, INC. Charts.

Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the second quarter ended June 30, 2013 on Wednesday, August 7, 2013 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). 

Receptos management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (866) 757-6808 (domestic) or (760) 536-5211 (international), participant code 14394984. The webcast can be accessed live on the Investor Relations section of the Receptos website at www.receptos.com and will be archived for 14 days following the call. A replay of the call will be available by phone by calling (855) 859-2056, participant code 14394984. 

About Receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).

CONTACT: Media and Investor Contact:
         Graham K. Cooper
         Chief Financial Officer, Receptos
         (858) 652-5708
         gcooper@receptos.com

1 Year RECEPTOS, INC. Chart

1 Year RECEPTOS, INC. Chart

1 Month RECEPTOS, INC. Chart

1 Month RECEPTOS, INC. Chart

Your Recent History

Delayed Upgrade Clock